{"disease":{"id":"venetoclax","name":"venetoclax"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05457361","title":"VAH Versus VA for Salvage Therapy of R/R-AML","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":162,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06073730","title":"Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":154,"lead_sponsor_name":"The Second Affiliated Hospital of Kunming Medical University","has_results":false},{"nct_id":"NCT07238907","title":"A Multi-center Retrospective Study of INO Treating B-ALL","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":102,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05841771","title":"Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT05893472","title":"A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":45,"lead_sponsor_name":"ZePing Zhou","has_results":false},{"nct_id":"NCT04454580","title":"Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy","phase":"","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Ospedale Maggiore Di Trieste","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}